Jane Street’s Protalix BioTherapeutics PLX Stock Holding History

Jane Street’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$91.6K	Sell	39,300 -18,700	-32%	-$39.6K	﹤0.01%	10647
2026 Q1	$126K	Buy	+58,000	New	+$144K	﹤0.01%	10504
2024 Q1	–	Sell	-17,100	Closed	-$30.4K	–	9885
2023 Q4	$30.4K	Hold	17,100	–	–	﹤0.01%	8864
2023 Q3	$28.4K	Sell	17,100 -17,500	-51%	-$31.4K	﹤0.01%	8257
2023 Q2	$69.2K	Buy	+34,600	New	+$82.4K	﹤0.01%	8136
2021 Q4	–	Sell	-119,600	Closed	-$159K	–	10652
2021 Q3	$159K	Sell	119,600 -51,600	-30%	-$78.4K	﹤0.01%	9022
2021 Q2	$327K	Buy	171,200 +140,100	+450%	+$482K	﹤0.01%	8001
2021 Q1	$139K	Buy	+31,100	New	+$145K	﹤0.01%	8497

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Jane Street's PLX Position: Q2 2026 in Review

Jane Street increased its Protalix BioTherapeutics (PLX) stake by 3.9% in Q2 2026, buying an estimated $1.44K and bringing the position to 18,020 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #10999.

Jane Street first reported a position in PLX in Q2 2013 and has held it in 48 quarters since. The position peaked at $753K in Q1 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Jane Street held 18,020 shares of Protalix BioTherapeutics worth $42K as of Q2 2026.
Jane Street bought 678 Protalix BioTherapeutics shares in Q2 2026, an estimated $1.44K.
Protalix BioTherapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10999 holding.
Jane Street first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 48 quarters since.
Jane Street's Protalix BioTherapeutics position peaked at $753K in Q1 2025.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.